Literature DB >> 1824831

Natural autoantibodies may play a role in ineffective erythropoiesis during megaloblastic haemopoiesis.

E Wiener1, S N Wickramasinghe.   

Abstract

Marrow aspirates from 11 patients with megaloblastic haemopoiesis and from 14 healthy individuals with normoblastic haemopoiesis were studied for antibodies associated with polychromatic/orthochromatic erythroblasts, using an 125I-labelled anti-human immunoglobulin reagent and autoradiography. In addition, the expression on these cells of receptors for FcIgG (FcR) and of the type I receptor for fragments of the third complement component (CR1) were investigated with receptor-specific monoclonal antibodies, 125I-labelled anti-mouse immunoglobulin and autoradiography. The percentages of immunoglobulin-positive erythroblasts were significantly greater in the megaloblastic than in the normoblastic marrows. Abnormally high percentages of labelled erythroblasts were present in patients without any manifestations of an autoimmune disorder. The percentage of labelled erythroblasts in the marrows of the patients correlated well with the degree of anaemia. FcR were absent on the majority of megaloblasts or normoblasts while the expression of CR1 was similar in both types of cell. The difference between the percentage labelling of megaloblasts and normoblasts was therefore unlikely to be due to greater binding of immune complexes with or without associated complement to megaloblasts than normoblasts. The megaloblast-bound immunoglobulin is, therefore, likely to have recognized abnormally expressed epitopes on the surface of megaloblasts. The results suggest that natural autoantibodies play a role in the destruction of erythroblasts during megaloblastic haemopoiesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824831      PMCID: PMC1535457          DOI: 10.1111/j.1365-2249.1991.tb05600.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

Review 1.  Function and heterogeneity of human Fc receptors for immunoglobulin G.

Authors:  J C Unkeless
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

2.  Differences between the activities of human monoclonal IgG1 and IgG3 subclasses of anti-D(Rh) antibody in their ability to mediate red cell-binding to macrophages.

Authors:  E Wiener; A Atwal; K M Thompson; M D Melamed; B Gorick; N C Hughes-Jones
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

Review 3.  Membrane complement receptors specific for bound fragments of C3.

Authors:  G D Ross; M E Medof
Journal:  Adv Immunol       Date:  1985       Impact factor: 3.543

4.  The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1.

Authors:  G J Dougherty; Y Selvendran; S Murdoch; D G Palmer; N Hogg
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

5.  Biochemically damaged erythroblasts bind natural serum antibodies and activate complement.

Authors:  E Wiener; R Dang; L Levy; S N Wickramasinghe
Journal:  Br J Exp Pathol       Date:  1987-12

6.  Immunoenzymatic staining of haematological samples with monoclonal antibodies.

Authors:  D J Moir; A K Ghosh; Z Abdulaziz; P M Knight; D Y Mason
Journal:  Br J Haematol       Date:  1983-11       Impact factor: 6.998

7.  A quantitative antiglobulin test for IgG for use in blood transfusion serology.

Authors:  A H Merry; E E Thomson; V I Rawlinson; F Stratton
Journal:  Clin Lab Haematol       Date:  1982

Review 8.  Deoxyuridine suppression: biochemical basis and diagnostic applications.

Authors:  S N Wickramasinghe; J H Matthews
Journal:  Blood Rev       Date:  1988-09       Impact factor: 8.250

9.  Erythroid Fc-IgG and complement receptor expression: a study of normoblastic and megaloblastic human bone marrows.

Authors:  A G Bynoe; C S Scott; B E Roberts
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

10.  Impaired protein synthesis in erythroblasts enhances their phagocytosis by macrophages.

Authors:  E Wiener; S N Wickramasinghe
Journal:  Br J Haematol       Date:  1983-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.